Save the Date

2012 SPONSORS

Leadership Council


Platinum Sponsors


Gold Sponsors

Silver Sponsors

Bronze Sponsors

Supporting Organizations

Despite Progress, Cancer Still Remains a Major Health Burden
Funding Innovative New Medicines: Where is the Money?
Evolution or Revolution? Transforming How Basic Research Discoveries Become Life Saving Therapies
Insights From Innovative Deals Between Academic Scientists, Biotech and Pharma
Raising Money, Attracting Collaborators:  Value Creation Starts with an Eye Towards Due Diligence
Applied Medical Research:  An Evolving Paradigm Focused on Patients
The Current Venture Landscape & Evolving Venture Strategies:  Considerations for Management of Emerging Companies
Filling the Pipeline:  An Overview of the Trends and Initiatives that will Influence Drug Development
On the Cusp of a New Era in Drug Development
Despite Progress, Cancer Still Remains a Major Health BurdenJonathan Lewis, MD, ZIOPHARM and Larry Norton MD, Memorial Sloan Kettering Cancer Center, Oncology KOL Session (2012)

Summit Highlights for 2013

Past Speakers

  • Bruce Stillman, Cold Spring Harbor Laboratory
  • Marc Tessier-LaVigne, The Rockefeller University
  • Afia Asamoah, Covington & Burling
  • Zafrira Avnur, PhD, Roche Partnering
  • Glenn Batchelder, Civitas Therapeutics
  • Karen Bernstein, PhD, BioCentury Publications
  • Joshua H. Bilenker, MD, Aisling Capital
  • Laurence Blumberg, MD, Kadmon Corporation
  • Anthony Caggiano, MD, PhD, Acorda Therapeutics
  • Pamela Carroll, PhD, Janssen/JNJ Innovation Center
  • Stephen Chang, PhD, New York Stem Cell Foundation
  • Sohini Chowdhury, The Michael J. Fox Foundation for Parkinson’s Research
  • Ron Cohen, MD, Acorda Therapeutics, Inc.
  • Timothy Coetzee, PhD, National Multiple Sclerosis Society
  • Ellen B. Corenswet, Covington & Burling
  • Mark Day, PhD, Bristol-Myers Squibb Company
  • Pamela R. Demain, MBA, Merck
  • Eric Elenko, PhD, PureTech Ventures
  • Howard M. Fillit, MD, Alzheimer’s Drug Discovery Foundation
  • Vincent Fishchetti, PhD, The Rockefeller University
  • James Foley, PhD, AQUA Partners
  • Steven C. Gilman, PhD, Cubist Pharmaceuticals
  • Julia P. Gregory, ContraFect
  • Baruch Harris, PhD, Enlight Biosciences
  • Cláudia Hirawat, PTC Therapeutics
  • Nancy J. Kelley, JD, MPP, New York Genome Center
  • Avi Kometz, MD, Ascent Biomedical Ventures
  • Jonathan S. Leff, Warburg Pincus
  • Jonathan Lewis, MD, PhD, ZIOPHARM Oncology
  • Yung S. Lie, PhD, Damon Runyon Cancer Research Foundation
  • Gail K. Naughton, PhD, Histogen
  • Ronald Newbold, PhD, Pfizer
  • Larry Norton, MD, Memorial Sloan-Kettering Cancer Center
  • William S. Podd, Landmark Angels
  • Rajesh Ranganathan, PhD, National Institutes of Health
  • Charles Ryan, JD, PhD, Forest Laboratories, Inc.
  • John Ryan, PhD, MD, Kadmon Corporation
  • Mark J.Simon, MBA, Torreya Partners
  • Neal G. Simon, PhD, Azevan Pharmaceuticals
  • Barbara S. Slusher, PhD, MAS, Johns Hopkins University
  • Deborah Somerville, Kenyon & Kenyon
  • Mel Spigelman, MD, TB Alliance
  • Mervyn J. Turner, PhD, MJTurner Consulting
  • Gregory Wiederrecht, PhD,  Merck
  • Matthew A. Wikler, MD, The Medicines Company